Science News

... from universities, journals, and other research organizations

Combination Of Laser And Topical Skin Ointment Effective In Treating The Skin Disease Vitiligo

Sep. 28, 2004 — CHICAGO -- Patients with vitiligo, a skin disorder characterized by patches of white, or de-pigmented skin, had better repigmentation of these patches when they were treated with a combination of laser therapy and tacrolimus ointment than patients treated with laser therapy alone, according to an article in the September issue of the Archives of Dermatology, one of the JAMA/Archives journals.


Share This:

According to the article, vitiligo is a skin pigmentation disorder that affects one percent to two percent of people worldwide. Patients with vitiligo develop white patches on their skin, referred to as "lesions." Recently, the 308-nm (nanometer) excimer laser has been used to treat lesions associated with vitiligo with good results. Additionally, a new topical ointment called tacrolimus has shown promise in treating vitiligo.

Thierry Passeron, M.D., of Hopital de l'Archet, Nice, France, and colleagues investigated the effects of the 308-nm excimer laser in combination with tacrolimus on 14 patients with vitiligo aged 12 to 63 years.

For each patient, four to ten lesions were chosen and treated twice a week with the 308-nm excimer laser for a total of 24 sessions. Topical 0.1 percent tacrolimus ointment was applied twice daily to target lesions for patients in group A (excimer laser plus tacrolimus). Patients in group B received only the laser treatments. Treated lesions were compared with control lesions (that received no treatment) on the opposite side of the body. Forty-three lesions were treated (23 in group A and 20 in group B).

The researchers observed repigmentation in all group A lesions (100 percent) and in 17 (85 percent) of the 20 group B lesions. Repigmentation was not observed in the control lesions.

"A repigmentation rate of 75 percent or more was obtained in 16 (70 percent) of the 23 group A lesions and in 4 (20 percent) of the 20 group B lesions," the authors write.

The average number of sessions needed to see an improvement in repigmentation was 10 for group A and 12 for group B.

"The combination of 0.1 percent tacrolimus ointment applied twice daily and 308-nm excimer laser therapy performed twice a week gives excellent results on UV-sensitive and UV-resistant areas. The treatment was well tolerated, and the patients were satisfied," the researchers conclude.

###

(Arch Dermatol. 2004;140:1065-1069. Available post-embargo at http://archdermatol.com)

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Journal Of The American Medical Association.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,376

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Follow ScienceDaily on Facebook, Twitter,
and Google:

Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Healing Rosacea

Antibiotics have been the traditional treatment for the skin disorder rosacea, but patients often develop antibiotic resistance to the drugs. A drug. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: